Efficacy of tralokinumab after failure with upadacitinib and dupilumab in a patient affected by atopic dermatitis

Efficacy of tralokinumab after failure with upadacitinib and dupilumab in a patient affected by atopic dermatitis

Bibliographic Details
Main Authors:	L. Mastorino, F. Gelato, P. Quaglino, M. Ortoncelli, S. Ribero
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2023-12-01
Series:	Journal of Dermatological Treatment
Online Access:	http://dx.doi.org/10.1080/09546634.2022.2153578

Similar Items

Is Dupilumab as Effective in Intrinsic Atopic Dermatitis as It Is in Extrinsic Atopic Dermatitis?
by: Federica Gelato, et al.
Published: (2023-03-01)

Long-Term Efficacy and Safety of Dupilumab in Patients with Atopic Dermatitis: A Single-Centre Retrospective Study
by: Michela Ortoncelli, et al.
Published: (2023-11-01)

Injection site reactions after dupilumab or tralokinumab for atopic dermatitis
by: Fabrizio Martora, et al.
Published: (2024-12-01)

Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis
by: Steven J Edwards, et al.
Published: (2024-01-01)

Chronic Pruritus in Atopic Patients Treated with Dupilumab: Real Life Response and Related Parameters in 354 Patients
by: Luca Mastorino, et al.
Published: (2022-07-01)

Atopic dermatitis treated with tralokinumab and upadacitinib combination therapy: A case report
by: Rafael Paolo Lansang, et al.
Published: (2023-06-01)

Effectiveness and safety of upadacitinib in patients with face and neck atopic dermatitis unresponsive to dupilumab
by: Yan Yang, et al.
Published: (2023-12-01)

Effectiveness of treatment of tralokinumab in treatment of atopic dermatitis in adolescents
by: Sameen Tahira, et al.
Published: (2023-10-01)

Immediate exacerbation of atopic dermatitis after switching from upadacitinib to dupilumab: A report of two cases
by: Makoto Ito, et al.
Published: (2023-10-01)

Paradoxical tralokinumab-induced psoriasis in a patient with atopic dermatitis
by: Galina Balakirski, et al.
Published: (2023-12-01)

Pharmacoeconomical analysis of the use of upadacitinib, baricitinib and dupilumab for systemic therapy of patients with moderate and severe atopic dermatitis
by: S. K. Zyryanov, et al.
Published: (2023-07-01)

Efficacy and safety of abrocitinib and upadacitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: A systematic review and meta-analysis
by: Qin Gao, et al.
Published: (2023-06-01)

Efficacy of dupilumab in moderate and severe atopic dermatitis
by: Stephan Weidinger, et al.
Published: (2023-06-01)

Real‐life case‐series experience with tralokinumab in patients with severe atopic dermatitis
by: Francesca Caroppo, et al.
Published: (2024-03-01)

Therapeutic Potential of Tralokinumab in the Treatment of Atopic Dermatitis: A Review on the Emerging Clinical Data
by: Kelly KA, et al.
Published: (2022-06-01)

Effectiveness of Upadacitinib in Patients with Atopic Dermatitis including those with Inadequate Response to Dupilumab and/or Baricitinib: Results from the BioDay Registry
by: Celeste M. Boesjes, et al.
Published: (2023-02-01)

Drug Survival of Upadacitinib and Predicting Factors of Discontinuation in Adult Patients Affected by Moderate-to-Severe Atopic Dermatitis: An Italian Multicenter Analysis
by: Elena Pezzolo, et al.
Published: (2024-01-01)

Retreatment with upadacitinib in atopic dermatitis: experience in clinical practice
by: S. Martínez-Fernández, et al.
Published: (2023-12-01)

Atopic Dermatitis and Ulcerative Colitis Successfully Treated with Upadacitinib
by: Teresa Grieco, et al.
Published: (2023-03-01)

Experience with dupilumab in patients with atopic dermatitis
by: E. A. Glukhova, et al.
Published: (2023-07-01)

Efficacy and safety of dupilumab in two adolescents with severe atopic dermatitis
by: Mara Giavina-Bianchi, et al.
Published: (2021-05-01)

Pharmacokinetics, pharmacodynamics, and exposure–efficacy of dupilumab in adults with atopic dermatitis
by: Mohamed A. Kamal, et al.
Published: (2022-10-01)

Real-World Experience with Tralokinumab in a Patient with Recalcitrant Atopic Dermatitis: A Case Report
by: Moennig E, et al.
Published: (2022-12-01)

Efficacy and Safety of Upadacitinib for Management of Moderate-to-Severe Atopic Dermatitis: An Evidence-Based Review
by: Yuliya Lytvyn, et al.
Published: (2022-11-01)

Treatment of atopic dermatitis with upadacitinib: adcare single center experience
by: Daria S. Fomina, et al.
Published: (2024-04-01)

Predictive factors for responders to upadacitinib treatment in patients with atopic dermatitis
by: Teppei Hagino, et al.
Published: (2024-12-01)

Exacerbation of human papillomavirus infection with initiation of upadacitinib for atopic dermatitis
by: Emily Seale, MPH, et al.
Published: (2023-06-01)

Periocular molluscum contagiosum in an atopic dermatitis patient treated with upadacitinib
by: E. De Luca, et al.
Published: (2022-10-01)

Upadacitinib as a treatment for chronic pruritus secondary to polycythemia vera after failure with dupilumab
by: Christopher I. Wachuku, MS, et al.
Published: (2023-05-01)

Upadacitinib for the treatment of concomitant psoriasis and atopic dermatitis: a case series
by: Luigi Gargiulo, et al.
Published: (2023-12-01)

Dupilumab and prurigo nodularis-like phenotype in atopic dermatitis: our experience of efficacy
by: S. Ferrucci, et al.
Published: (2021-05-01)

Uveitis and hypereosinophilia associated with dupilumab in an atopic dermatitis patient
by: Shiyu Zhang, et al.
Published: (2023-12-01)

Dupilumab in atopic dermatitis patients with chronic hepatitis B
by: Masako Matsutani, et al.
Published: (2022-04-01)

The application of the biological treatment in atopic dermatitis: focus on dupilumab
by: Yu. S. Smolkin, et al.
Published: (2023-03-01)

Punctal stenosis associated with dupilumab therapy for atopic dermatitis
by: Debora H. Lee, et al.
Published: (2021-10-01)

Dupilumab for the treatment of adult atopic dermatitis in special populations
by: Cataldo Patruno, et al.
Published: (2022-10-01)

Efficacy and safety of upadacitinib for the treatment of moderate-to-severe atopic dermatitis: a systematic review and meta-analysis
by: Yuanjie Huang, et al.
Published: (2024-01-01)

Retrospective Study of Dupilumab Treatment for Moderate to Severe Atopic Dermatitis in Korea: Efficacy and Safety of Dupilumab in Real-World Practice
by: Dong Hyek Jang, et al.
Published: (2020-06-01)

Eosinophilic pneumonia developed after dupilumab administration in a patient with atopic dermatitis
by: Kei Kanata, et al.
Published: (2023-08-01)

Dupilumab Provides Rapid and Sustained Improvement in SCORing Atopic Dermatitis Outcomes in Paediatric Patients with Atopic Dermatitis
by: Andreas Wollenberg, et al.
Published: (2022-05-01)